MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $14.33 (13.13% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetActions
8/3/2015Needham & Company LLCReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/3/2015WedbushBoost Price TargetOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2015Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015WedbushReiterated RatingOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015WedbushReiterated RatingOutperform$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Needham & Company LLCReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2015WedbushReiterated RatingOutperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2015WedbushReiterated RatingOutperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Stifel NicolausLower Price TargetBuy$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Stifel NicolausReiterated RatingBuy$4.00 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014GabelliDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/6/2013Bank of AmericaInitiated CoverageUnderperform$1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/11/2013GabelliReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/5/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha